Symposia
Controlled human malaria infection as a tool to accelerate the drug development of novel antimalarial drugs

Symposium organizer: Jörg Möhrle  
Medicines for Malaria Venture, Switzerland

Co-Chair: Peter Kremsner  
Tübingen University, Germany

Speakers and topics:

- **Mosquito challenge studies for the evaluation of chemoprotection potential of new antimalarial drugs**  
  James Kublin, Seattle BioMed, USA

- **Cryopreserved sporozoite challenge studies, a new concept to test antimalarial candidates**  
  Benjamin Mordmüller, Tübingen University, Germany

- **Blood-stage challenge studies to evaluate activity against asexual and transmission stages**  
  James McCarthy, QIMR Berghofer Medical Research Institute, Australia

- **How can malaria challenge studies improve clinical studies in the field and shorten the time to patients?**  
  Jörg Möhrle, Medicines for Malaria Venture, Switzerland
Symposium 68

Safety update on ACTs in sub-Saharan Africa: review of more than 34,000 malaria attacks in three pharmacovigilance studies

Symposium organizer: Stephan Duparc
Medicines for Malaria Venture, Switzerland

Speakers and topics:

- **A review of new safety data for pyronaridine-artesunate and dihydroartemisinin-piperaquine in more than 4,500 children and adult patients with acute, uncomplicated *P. falciparum* malaria**
  Abdoulaye Djimde, University of Science Techniques and Technologies, Bamako, Mali

- **Longitudinal study comparing artesunate-amodiaquine to artemether-lumefantrine, carried out in Tororo, Uganda with more than 6,000 malaria attacks reported over a 2-year follow-up period in 413 children**
  Wilfred Mbacham, University of Yaounde I, Cameroon

- **Safety evaluation of artesunate-amodiaquine in a Cohort Event Monitoring study carried out in 15,000 patients from the district of Agboville in Côte d'Ivoire**
  Christophe Rogier, Institut Pasteur de Madagascar, Madagascar

- **Strengthening pharmacovigilance through collaborative support frameworks**
  Alex Dodoo, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, Ghana
Emerging technologies and advances in drug discovery for liver stages of *Plasmodium vivax*

**Symposium organizer:** Dennis Kyle  
University of South Florida, USA  
**Co-chair:** Brice Campo  
Medicines for Malaria Venture, Switzerland

**Speakers and topics:**

- **Advantages of screening for new drugs in a hepatoma cell line**  
Jetsumon Sattabongkot Prachumsri, Mahidol University, Thailand

- **Microscale models of human liver as a platform for drug development**  
Sandra March, Massachusetts Institute of Technology, USA

- **Novel devices for primary human hepatocyte physiology and high-throughput drug screening for *P. vivax***  
Steven Maher, Draper Laboratory Bioengineering Center, USA

- **Defining the biology of the elusive hypnozoite in humanized mouse models of disease**  
Sebastian Mikolajczak, Seattle Biomedical Research Institute, USA
Dihydroartemisinin/piperaquine and the latest achievements in uncomplicated malaria treatment

Chair: George Jagoe  
Medicines for Malaria Venture, Switzerland

Speakers and topics:

- **Modelling the impact of DHA-PQP on malaria transmission and comparison with other ACTs**  
  Lucy Okell, Imperial College, UK

- **The safety and efficacy of four artemisinin-based combination treatments in pregnant African women with malaria**  
  Umberto D’Alessandro, Medical Research Council, Banjul, Gambia

- **Clinical development of the antimalarial dihydroartemisinin/piperaquine in Manhiça, Mozambique – past, present and future**  
  Quique Bassat, Barcelona Institute of Global Health (ISGlobal), Spain and Centro de Investigação e Saude da Manhiça, Mozambique

- **The burden of drug-resistant *P. Falciparum* malaria: where does dihydroartemisinin/piperaquine stand?**  
  Rick Fairhurst, National Institute of Allergy and Infectious Diseases, USA
Scientific session
97: Malaria: Drug Development – Preclinical to Phase IV

Co-chair: Justin Green
GlaxoSmithKline, UK
Co-chair: Amanda Lukens
The Broad Institute, USA

MMV and partner speakers and topics:

4.30 pm. 1207  A dose-ranging clinical trial to evaluate the pharmacokinetics and pharmacodynamics of the combination of DSM265 and OZ439 in a Plasmodium falciparum Induced Blood-Stage Malaria system
Presenter: James S. McCarthy, QIMR Berghofer Medical Research Institute, Australia

5.00 pm. 1209  Drug-drug interaction study of tafenoquine and the ACTs dihydroartemisinin-piperaquine (DHA-PQP) and artemether-lumefantrine (AL)
Presenter: Justin Green, GlaxoSmithKline, UK
Poster Session A

220  Recrudescent *Plasmodium falciparum* isolates from DHA-piperaquine failures in Cambodia: \textit{in-vitro} susceptibility to newer antimalarial drugs

Presenter  Vorleak Try, National Center for Parasitology, Entomology and Malaria Control, Cambodia

229  Health workers’ knowledge on administration of injectable artesunate for treatment of severe malaria in Oromia and SNNPR region, Ethiopia

Presenter  Zelalem Kebede, Malaria Consortium, Ethiopia
## Poster sessions

**Poster Session B**

Tuesday 27 Oct  
12.00 pm to 1.45 pm

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>733</td>
<td>Enhancement of <em>P. vivax</em> oocyst production in <em>Anopheles darlingi</em> experimental infections</td>
<td>Carlos Tong, Universidad Peruana Cayetano Heredia, Peru</td>
</tr>
<tr>
<td>815</td>
<td>A multi-stage preclinical candidate for the potential treatment of malaria</td>
<td>Neil Norcross, Drug Discovery Unit, University of Dundee, UK</td>
</tr>
<tr>
<td>852</td>
<td>A quantitative tool for assessing ideal drug combinations for malaria therapy</td>
<td>Wesley Van Voorhis, University of Washington, USA</td>
</tr>
<tr>
<td>857</td>
<td>A Phase IIa proof-of-concept study to assess the efficacy, safety, tolerability and pharmacokinetics of single doses of DSM265 in adult patients with acute, uncomplicated <em>Plasmodium falciparum</em> or <em>vivax</em> malaria mono-infection over a 28-day-extended observation period in Iquitos, Peru</td>
<td>Thomas Rueckle, Medicines for Malaria Venture, Switzerland</td>
</tr>
<tr>
<td>860</td>
<td>Development of a controlled human malaria infection model for the assessment of transmission blocking interventions</td>
<td>Katharine Collins, QIMR Berghofer Medical Research Institute, Australia</td>
</tr>
<tr>
<td>889</td>
<td>The burden of malaria infection among young African infants in different malaria transmission settings</td>
<td>Jane Achan, MRC Unit, Banjul, Gambia</td>
</tr>
</tbody>
</table>